NUVB Nuvation Bio Inc.
USHealthcareAs of 2026-07-09 16:00
Why NUVB matters now
Nuvation Bio Inc. (NUVB) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.11 with +4.09% on the session and $2.12B in market capitalization; recent performance reads 1-month +31.13% and YTD -37.95%.
The latest financial table shown here is Q1 2026, with revenue of $83.2M, net income of $5.4M, and EPS of $0.01. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.5%.
The latest indexable market news headline is "Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.50; recent insider activity includes Mashal Robert filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.04
P/S
13.50
EV/EBITDA
-13.99
DCF Value
$3.38
FCF Yield
-6.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.6%
Operating Margin
-105.0%
Net Margin
-102.1%
ROE
-44.1%
ROA
-23.9%
ROIC
-27.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $83.2M | $5.4M | $0.01 |
| Q4 2025 | $41.9M | $-36.6M | $-0.11 |
| FY 2025 | $62.9M | $-204.6M | $-0.60 |
| Q3 2025 | $13.1M | $-55.8M | $-0.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$13.00
Target (Median)
$12.50
Target Range
$10.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.56
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.